Due to the rising prevalence and significant burden of Alzheimer’s disease there is a critical need for continuing education aimed at bridging existing gaps in clinician knowledge, competence, and performance concerning novel and emerging amyloid-targeting therapies (ATTs), especially in the early symptomatic stages of AD where timely and optimal intervention can significantly alter patient outcomes. By fostering a nuanced understanding of AD neuropathology, biomarker relevance, and the practical application of ATTs, this initiative proposes to equip global dementia specialists, neurologists, geriatricians, and geriatric psychiatrists with the essential knowledge and skills required to improve the diagnostic accuracy and therapeutic management of AD.
In this CMEO Snack entitled, Early Detection, Better Direction: Tau Biomarkers and Amyloid-Targeting Therapies in Alzheimer’s Disease, expert faculty will discuss strategies for identifying the neuropathological chances associated with AD, assessing the role of phosphorylated tau biomarkers, evaluating latest data from clinical trials on ATTs, and identifying appropriate patients to ensure timely and optimal management.
At the conclusion of this activity, learners will be able to better:
Supported through an independent educational grant from Lilly.
Physicians, physician associates (PAs), and nurse practitioners (NPs) specializing in dementia, psychiatry, neurology, or geriatrics
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.
Note to Physician Associates: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.
Dr. Atri reports the following financial relationships:
Advisory Board: Eisai Inc.; Lundbeck; Merck & Co., Inc.; Novo Nordisk; and Roche/Genentech, Inc.
Consultant: Eisai Inc.; Lundbeck; Merck; Novo Nordisk; Prothena; and Roche/Genentech, Inc.
Grants: (Institutional research grant/contract funding): Arizona Department of Health Services; Foundation for National Institutes of Health (FNIH); Gates Ventures; National Institute on Aging (NIA/NIH; and Washington University St Louis (as Project Arm Leader for DIAN-TU)
Research Support (Institutional research support or grants for observational or biomarker studies or clinical trials): Alzheimer’s Disease Consortia – Coordinating research institutes or government funding (Alzheimer’s Clinical Trials Consortium (ACTC); Alzheimer’s Disease Cooperative Study (ADCS); Alzheimer’s Therapeutic Research Institute; (ATRI); National Institutes of Health (NIH); Athira Pharma, Inc.; Alzheon, Inc.; Biohaven (with ADCS); Eisai Inc. (with ATRI/ACTC); Global Alzheimer’s Platform Foundation; Indiana University (observational cohort); Johns Hopkins (clinical trial); Lilly (with ACTC/NIH); PEACE-AD Study (with ADCS); Vivoryon (with ADCS)
Dr. Zetterberg reports the following financial relationships:
Advisory Board/Consultant: AbbVie Inc.; Acumen Pharmaceuticals, Inc.; Alector, Inc.; Alzinova; ALZPath Inc.; Annexon Biosciences; Apellis Pharmaceuticals; Artery Therapeutics, Inc.; AZTherapies, Inc.; Cognito Therapeutics; Cognition Therapeutics; Denali Therapeutics; Eisai Europe Ltd; Merry Life; NervGen Pharma Corp.; Novo Nordisk; OptoCeutics; Passage Bio; Pinteon Therapeutics; Prothena; Red Abbey; reMYND; Roche; Samumed; Siemens Healthineers; Triplet Therapeutics, Inc.; and Wave Life Sciences
Speakers Bureau: AlzeCure Pharma; Biogen; Cellectricon; Fujirebio; Lilly; Novo Nordisk; and Roche
Stock Shareholder (ownership interest): Co-founder and stock shareholder of Brain Biomarker Solutions in Gotheburg AB (BBS), which is a part of the GU Ventures Incubator Program
The following individuals have no financial relationships to disclose:
Thomas Heinrich, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Evan Luberger (Planning Committee)
Kellie Busby, PharmD, BCPP (Planning Committee)
Erin Spencer (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Call us at 877.CME.PROS (877.263.7767).
SN-231-040124-11
